Soon Patsy Siok Hwa, Tacon Lyndal J, Gill Anthony J, Bambach Christopher P, Sywak Mark S, Campbell Peter R, Yeh Michael W, Wong Steven G, Clifton-Bligh Roderick J, Robinson Bruce G, Sidhu Stan B
Authors' Affiliations: Cancer Genetics, Kolling Institute of Medical Research; Department of Endocrinology; Department of Anatomical Pathology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Surgery, Bankstown Hospital, Bankstown, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales; Endocrine Surgical Unit, University of Sydney; Department of Surgery, Liverpool Hospital, Sydney, New South Wales, Australia; Endocrine Surgical Unit, University of California Los Angeles; and Division of Hematology and Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California.
Clin Cancer Res. 2009 Dec 15;15(24):7684-7692. doi: 10.1158/1078-0432.CCR-09-1587.
Adrenocortical adenomas are common, whereas adrenocortical carcinomas are rare. Discriminating between benign and malignant adrenocortical tumors using conventional histology can be difficult. In addition, adrenocortical carcinomas generally have poor prognosis and limited treatment options. MicroRNAs are short noncoding RNAs that are involved in regulation of gene transcription. EXPERIMENTAL DESIGN: To identify microRNAs involved in the pathogenesis of adrenocortical tumors, expression profiling of microRNAs was done on a cohort of 22 adrenocortical carcinomas, 27 adrenocortical adenomas, and 6 normal adrenal cortices. RESULTS: Twenty-three microRNAs were found to be significantly differentially expressed between adrenocortical carcinomas and adrenocortical adenomas. miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas compared with adrenocortical adenomas. This result was further validated in an external cohort of six adrenocortical carcinomas and four adrenocortical adenomas. Using Kaplan-Meier analysis, downregulation of miR-195 and upregulation of miR-483-5p in adrenocortical carcinomas were significantly associated with poorer disease-specific survival. CONCLUSIONS: These findings indicate that deregulation of microRNAs is a recurring event in human adrenocortical carcinomas and that aberrant expression of miR-195 and miR-483-5p identifies a subset of poorer prognosis adrenocortical carcinomas. (Clin Cancer Res 2009;15(24):7684-92).
肾上腺皮质腺瘤很常见,而肾上腺皮质癌则很罕见。使用传统组织学方法区分良性和恶性肾上腺皮质肿瘤可能很困难。此外,肾上腺皮质癌通常预后较差且治疗选择有限。微小RNA是参与基因转录调控的短链非编码RNA。
为了鉴定参与肾上腺皮质肿瘤发病机制的微小RNA,对22例肾上腺皮质癌、27例肾上腺皮质腺瘤和6例正常肾上腺皮质进行了微小RNA表达谱分析。
发现23种微小RNA在肾上腺皮质癌和肾上腺皮质腺瘤之间存在显著差异表达。与肾上腺皮质腺瘤相比,miR-335和miR-195在肾上腺皮质癌中显著下调。这一结果在一个由6例肾上腺皮质癌和4例肾上腺皮质腺瘤组成的外部队列中得到了进一步验证。使用Kaplan-Meier分析,肾上腺皮质癌中miR-195的下调和miR-483-5p的上调与较差的疾病特异性生存率显著相关。
这些发现表明,微小RNA的失调是人类肾上腺皮质癌中反复出现的事件,miR-195和miR-483-5p的异常表达确定了一部分预后较差的肾上腺皮质癌。(《临床癌症研究》2009年;15(24):7684 - 92)